دورية أكاديمية
أعرض في EDS

A Promising Diagnostic Role of Immunohistochemical Expression of Insulin-Like Growth Factor II mRNA Binding Protein 3 (IMP3) in Pancreatic Lesions Using Endoscopic Ultrasound-Guided Fine Needle Aspiration (EUS-FNA) Cytology.

التفاصيل البيبلوغرافية
العنوان: A Promising Diagnostic Role of Immunohistochemical Expression of Insulin-Like Growth Factor II mRNA Binding Protein 3 (IMP3) in Pancreatic Lesions Using Endoscopic Ultrasound-Guided Fine Needle Aspiration (EUS-FNA) Cytology.
المؤلفون: Rashed HE; Pathology Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt. hayam_rashed@yahoo.com., Nasr AN; Pathology Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt., Wasfi NT; Pathology Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt., ElHendawy R; Tropical Medicine Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt., Said NM; Pathology Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt.
المصدر: Journal of gastrointestinal cancer [J Gastrointest Cancer] 2023 Mar; Vol. 54 (1), pp. 96-103. Date of Electronic Publication: 2022 Jan 14.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Springer Science+Business Media Country of Publication: United States NLM ID: 101479627 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1941-6636 (Electronic) NLM ISO Abbreviation: J Gastrointest Cancer Subsets: MEDLINE
أسماء مطبوعة: Publication: 2010- : New York : Springer Science+Business Media
Original Publication: New York, NY : Humana Press
مواضيع طبية MeSH: Endoscopic Ultrasound-Guided Fine Needle Aspiration*/methods , Pancreatic Neoplasms*/diagnosis , Pancreatic Neoplasms*/pathology, Humans ; Prospective Studies
مستخلص: Background: Poor prognosis and short survival of patients harboring pancreatic cancer emerge how advanced disease it is. In a trial to achieve the earliest and most accurate diagnosis to manage this progressive disease, we proposed that using endoscopic ultrasound-guided fine needle aspiration (EUS-FNA) with an adjuvant diagnostic immunohistochemical marker would give better diagnostic results. IMP3 has gained recently wide attention, as many studies found that IMP3 has not only diagnostic but also prognostic role in different types of malignancies.
Aim of the Study: This prospective work is to assess the diagnostic role of EUS-FNA combined with the immunohistochemical expression of IMP3 on different benign and malignant pancreatic lesions.
Material and Method: The included pancreatic lesions (n = 140) were obtained by EUS-FNA technique and stained for IMP3 immunohistochemically. Paraffin blocks from patients who underwent excision (n = 92) or core biopsies (n = 48) were performed for confirming diagnosis.
Results: The combined method for diagnosis showed that IMP3 was positive in 78.7%, 91.7%, 100% PAC, mucinous neoplasm with high grade dysplasia, and IPMN with high grade dysplasia, respectively, while almost all benign lesions showed negative IMP3. Also, this method showed sensitivity (78.26%), specificity (95.83%), and accuracy (84.3%).
Conclusion: EUS-FNA cytology with IMP3 could be a reliable diagnostic tool especially for assessment of malignant pancreatic lesions.
(© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.)
References: American Cancer Society. Facts & figures 2021. Atlanta, Ga: American Cancer Society; 2021.
Howlader N, Noone AM, Krapcho M, et al (eds). SEER cancer statistics review, 1975–2017, National Cancer Institute, Bethesda, MD, https://seer.cancer.gov/csr/1975_2017/ , based on November 2018 SEER data submission, posted to the SEER website, April 2019.
Puli SR, Bechtold ML, Buxbaum JL, Eloubeidi MA. How good is endoscopic ultrasound-guided fine-needle aspiration in diagnosing the correct etiology for a solid pancreatic mass?: a meta-analysis and systematic review. Pancreas. 2013;42(1):20–6. (PMID: 10.1097/MPA.0b013e3182546e7923254913)
Nielsen FC, Nielsen J, Christiansen J. A family of IGF-II mRNA binding proteins (IMP) involved in RNA trafficking. Scand J Clin Lab Invest Suppl. 2001;234:93–9. (PMID: 10.1080/71378368011713986)
Mueller-Pillasch F, Pohl B, Wilda M, Lacher U, Beil M, Wallrapp C, Hameister H, Knöchel W, Adler G, Gress TM. Expression of the highly conserved RNA binding protein KOC in embryogenesis. Mech Dev. 1999;88(1):95–9. (PMID: 10.1016/S0925-4773(99)00160-410525192)
Yan J, Wei Q, Jian W, Qiu B, Wen J, Liu J, Fu B, Zhou X, Zhao T. IMP3 predicts invasion and prognosis in human lung adenocarcinoma. Lung. 2016;194:137–46. (PMID: 10.1007/s00408-015-9829-026608347)
Lok T, Chen L, Lin F, Wang HL. Immunohistochemical distinction between intrahepatic cholangiocarcinoma and pancreatic ductal adenocarcinoma. Hum Pathol. 2014;45:394–400. (PMID: 10.1016/j.humpath.2013.10.00424439226)
Damasceno EA, Carneiro FP, Magalhães AV, Carneiro MV, Takano GH, Vianna LM, Seidler HB, Castro TM, Muniz-Junqueira MI, Amorim RF, Ferreira VM. IMP3 expression in gastric cancer: association with clinicopathological features and HER2 status. J Cancer Res Clin Oncol. 2014;140:2163–8. (PMID: 10.1007/s00432-014-1850-925323937)
Li D, Yan D, Tang H, Zhou C, Fan J, Li S, Wang X, Xia J, Huang F, Qiu G, Peng Z. IMP3 is a novel prognostic marker that correlates with colon cancer progression and pathogenesis. Ann Surg Oncol. 2009;16(12):3499–506. (PMID: 10.1245/s10434-009-0648-519672661)
Burdelski C, Jakani-Karimi N, Jacobsen F, Möller-Koop C, Minner S, Simon R, Sauter G, Steurer S, Clauditz TS, Wilczak W. IMP3 overexpression occurs in various important cancer types and is linked to aggressive tumor features: a tissue microarray study on 8,877 human cancers and normal tissues. Oncol Rep. 2018;39(1):3–12. (PMID: 29115542)
Yan J, Wei Q, Jian W, Qiu B, Wen J, Liu J, Fu B, Zhou X, Zhao T. IMP3 predicts invasion and prognosis in human lung adenocarcinoma. Lung. 2016;194(1):137–46. (PMID: 10.1007/s00408-015-9829-026608347)
Pasiliao CC, Chang CW, Sutherland BW, Valdez SM, Schaeffer D, Yapp DT, Ng SS. The involvement of insulin-like growth factor 2 binding protein 3 (IMP3) in pancreatic cancer cell migration, invasion, and adhesion. BMC Cancer. 2015;15:266. (PMID: 10.1186/s12885-015-1251-8258863674403680)
Elshafey MR, Ahmed RA, Mourad MI, Gaballah ET. The oncofetal protein IMP3 is an indicator of early recurrence and poor outcome in mucoepidermoid carcinoma of salivary glands. Cancer Biol Med. 2016;13(2):286–95. (PMID: 10.20892/j.issn.2095-3941.2016.0037274585364944550)
Tanaka H, Kawashima H, Ohno E, Ishikawa T, Iida T, Ishikawa E, Furukawa K, Nakamura M, Honda T, Shimoyama Y, Miyahara R, Kawabe N, Kuzuya T, Hashimoto S, Ishigami M, Hirooka Y, Fujishiro M. Immunohistochemical staining for IMP3 in patients with duodenal papilla tumors: assessment of the potential for diagnosing endoscopic resectability and predicting prognosis. BMC Gastroenterol. 2021;21(1):224. (PMID: 10.1186/s12876-021-01811-8340062508130282)
Barton VN, Donson AM, Birks DK, Kleinschmidt-DeMasters BK, Handler MH, Foreman NK, Rush SZ. Insulin-like growth factor 2 mRNA binding protein 3 expression is an independent prognostic factor in pediatric pilocytic and pilomyxoid astrocytoma. J Neuropathol Exp Neurol. 2013;72(5):442–9. (PMID: 10.1097/NEN.0b013e31829023dd23584203)
Yantiss RK, Woda BA, Fanger GR, Kalos M, Whalen GF, Tada H, Andersen DK, Rock KL, Dresser K. KOC (K homology domain containing protein overexpressed in cancer): a novel molecular marker that distinguishes between benign and malignant lesions of the pancreas. The American J Surg Pathol. 2005;29(2):188–95. (PMID: 10.1097/01.pas.0000149688.98333.54)
Wang BJ, Wang L, Yang SY, Liu ZJ. Expression and clinical significance of IMP3 in microdissected premalignant and malignant pancreatic lesions. Clin Transl Oncol. 2015;17(3):215–22. (PMID: 10.1007/s12094-014-1216-425183049)
Wang Q, Wang T, Wang Z, Zheng H. Diagnostic value of IMP3 in pancreatic cancer: a meta-analysis [Retraction]. Int J Clin Exp Med. 2016;9(6):12417.
Zheng W, Yi X, Fadare O, Liang SX, Martel M, Schwartz PE, Jiang Z. The oncofetal protein IMP3: a novel biomarker for endometrial serous carcinoma. Am J Surg Pathol. 2008;32(2):304–15. (PMID: 10.1097/PAS.0b013e3181483ff818223334)
Yantiss RK, Cosar E, Fischer AH. Use of IMP3 in identification of carcinoma in fine needle aspiration biopsies of pancreas. Acta Cytol. 2008;52(2):133–8. (PMID: 10.1159/00032547018499984)
Zhao H, Mandich D, Cartun RW, Ligato S. Expression of K homology domain containing protein overexpressed in cancer in pancreatic FNA for diagnosing adenocarcinoma of pancreas. Diagn Cytopathol. 2007;35(11):700–4. (PMID: 10.1002/dc.2073917924416)
Liu H, Shi J, Anandan V, Wang HL, Diehl D, Blansfield J, Gerhard G, Lin F. Reevaluation and identification of the best immunohistochemical panel (pVHL, Maspin, S100P, IMP-3) for ductal adenocarcinoma of the pancreas. Arch Pathol Lab Med. 2012;136(6):601–9. (PMID: 10.5858/arpa.2011-0326-OA22646265)
Ezzat NE, Tahoun NS, Ismail YM. The role of S100P and IMP3 in the cytologic diagnosis of pancreatic adenocarcinoma. J Egypt Natl Canc Inst. 2016;28(4):229–34. (PMID: 10.1016/j.jnci.2016.10.00227839709)
Senoo J, Mikata R, Kishimoto T, Hayashi M, Kusakabe Y, Yasui S, Yamato M, Ohyama H, Sugiyama H, Tsuyuguchi T, Yoshitomi H, Ohtsuka M, Maeda J, Ota S, Nakatani Y, Kato N. Immunohistochemical analysis of IMP3 and p53 expression in endoscopic ultrasound-guided fine needle aspiration and resected specimens of pancreatic diseases. Pancreatology. 2018;18:176–83. (PMID: 10.1016/j.pan.2017.12.01029305088)
فهرسة مساهمة: Keywords: Endoscopic ultrasound-guided fine needle aspiration; IMP3; Immunohistochemistry; Pancreatic cancer
المشرفين على المادة: 0 (IGF2BP3 protein, human)
تواريخ الأحداث: Date Created: 20220114 Date Completed: 20230531 Latest Revision: 20230531
رمز التحديث: 20240628
DOI: 10.1007/s12029-021-00770-3
PMID: 35028828
قاعدة البيانات: MEDLINE
الوصف
تدمد:1941-6636
DOI:10.1007/s12029-021-00770-3